Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/14/2012

CRANBURY, N.J., Nov. 14, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2012. 

Recent Highlights
On July 3, 2012, Palatin closed on a private placement of 3,873,000 shares of its common stock, Series A 2012 warrants to purchase up to 31,988,151 shares of its common stock, and Series B 2012 warrants to purchase up to 35,488,380 shares of its common stock. Aggregate gross proceeds to Palatin were $35,000,000, with net proceeds, after deducting offering expenses, of $34,407,446.

On September 27, 2012, at a special meeting Palatin stockholders voted to increase its authorized common stock from 100,000,000 to 200,000,000 shares, and Palatin filed a certificate of amendment with the Secretary of State of Delaware the same day. This satisfied certain contractual obligations relating to the Series B 2012 warrants in its 2012 private placement, so that interest will not be payable on the value of the Series B 2012 warrants and Palatin will not be required to redeem the Series B 2012 warrants for failure to increase the number of authorized shares.

On November 8, 2012, Palatin reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD). The primary endpoint data analysis of 327 pre-menopausal women with female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or a combination of both disorders, the most common types of FSD, demonstrate that women taking bremelanotide showed clinically meaningful and statistically significant increases
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Tooth decay is an epidemic in American ... the disease. The World Health Organization says that worldwide, ... have cavities. What are the long-term effects of this transmissible ... connection between the oral bacterial imbalance and serious systemic issues ... yet it is also 100% preventable? Answer: there has been ...
(Date:5/16/2013)... 16, 2013 Oven Industries, Inc. has ... and temperature sensors since 1964. Expertly designed, ... industrial control system applications. As one of ... a generic, control loop feedback system, which helps minimize ... to adjust a systematic process, using a control element, ...
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth annual ... Renaissance Waterfront Hotel in Boston, MA. The ten ... the current strategies and innovations for optimizing bioprocesses while ... the field will reveal how their work has resulted ... and efficiency. , “In this age of rapid innovation, ...
(Date:5/16/2013)... , May 16, 2013  The registration deadline ... Bioscience Financial Officers (ABFO) 2013 National Conference, the premier ... held May 28-31 at the Hilton San Diego Bayfront. ... on this year,s conference and want to make sure ... attend," said Brandi Roberts , Chief ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3New PID Temperature Controllers Announced by Oven Industries Inc. 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... VIASPACE Inc. (OTC Bulletin Board: VSPC) announced today ... patent number 7, 499,169 to VIASPACE on March 3, ... water vapor (humidity) in gas streams for fuel cells ... and factory smokestacks. Inventors are Nathan Hurvitz and ...
... The long-awaited speaking faculty for the September Pharma ... the conference website reports Mark Alexay, President of ... is comprised of 100 speakers from pharmaceutical companies ... in the pipeline. The speaker list may be ...
... Modigene Inc. (OTC Bulletin Board: MODG), a biopharmaceutical company ... longer-acting versions of already approved therapeutic proteins, today announced ... BIO-Europe Spring(R) 2009 Conference at 10:00 AM (local time) ... held at the Milano Convention Center in Milan, Italy ...
Cached Biology Technology:VIASPACE Granted US Patent 2Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ 2
(Date:5/17/2013)... Why Tibetan antelope can live at elevations of ... research published in Nature Communications , investigators ... evidence that some genetic factors may be associated ... The data in this work will also provide ... biology of other ruminant species. , The Tibetan ...
(Date:5/17/2013)... An international team of scientists using a ... movement inside a living frog embryo in greater detail ... to advance biological research and the search for new ... the Karlsruher Institut fr Technologie in Germany, in collaboration ... of Energy,s Argonne National Laboratory, released the most precise ...
(Date:5/16/2013)... African-American adults living closer to a fast food restaurant ... who lived further away from fast food, according to ... Center, and this association was particularly strong among those ... published online in the American Journal of Public ... to a fast food restaurant, and among lower-income African-Americans, ...
Breaking Biology News(10 mins):The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2New X-ray method shows how frog embryos could help thwart disease 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... release is available in French . , Researchers ... of the Jewish General Hospital along with colleagues at ... (OHRI) report a significant breakthrough in the use of viruses ... oncolytic virotherapy. Their results were published in the September early ...
... Burnham Institute for Medical Research today announced that Stuart ... Del E. Webb Neuroscience, Aging, and Stem Cell Research ... five years, to establish a Center for Neurodegeneration Science ... Parkinson,s disease. Funding for the center comes from the ...
... Innes Centre and the Central Science Laboratory could help ... stress and climate change. The research also shows that ... the climate. "While many compounds have been reported ... have identified how such compounds change in crops under ...
Cached Biology News:Viral 'magic bullet' targets cancer cells with help of new compound 2Burnham researcher awarded $8 million grant 2
Polyclonal Antibody to CRTR-1...
Recognizes NSCL1. The molecular weight of the protein is 14,616 Daltons....
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
Biology Products: